Oral Delivery of Therapeutic Proteins and Peptides: An Overview of Current Technologies and Recommendations for Bridging from Approved Intravenous or Subcutaneous Administration to Novel Oral Regimens

Abstract

Since the early 1980s, therapeutic proteins and peptides have become established as an important class of pharmaceuticals. Due to their low oral bioavailability, which results from pre-systemic degradation and poor gastrointestinal absorption, most therapeutic proteins and peptides are administered intravenously. While subcutaneous formulations of some therapeutic proteins and peptides have been shown to improve patient convenience and reduce medical resource utilization, oral administration is generally the preferred administration route. Some therapeutic proteins and peptides employing novel oral delivery technologies have reached late-stage clinical development. To develop a new oral formulation of a therapeutic protein or peptide currently marketed as an injectable product, technical, nonclinical, and clinical studies are required to demonstrate similar safety and efficacy compared with the existing administration route. Since there is little experience with oral therapeutic proteins and peptides, this review provides recommendations for bridging from an approved intravenous or subcutaneous regimen to novel oral administration of the same therapeutic protein or peptide, based on precedents from intravenous-to-subcutaneous bridging approaches for trastuzumab, rituximab, tocilizumab, and bortezomib. If the pharmacokinetic/pharmacodynamic relationship is well characterized, demonstration of comparability in prespecified pharmacokinetic parameters might form a basis for establishing similar efficacy and safety of the oral formulation vs. the reference product. Although oral administration of therapeutic proteins and peptides remains challenging, given recent progress with novel delivery technologies, intravenous/subcutaneous-to-oral nonclinical and clinical bridging programs may soon be utilized to support approval of new oral formulations.

Key words

monoclonal antibody - pharmacokinetics - rituximab - tocilizumab - trastuzumab - bortezomib

• References

• 1 Carter PJ. Introduction to current and future protein therapeutics: a protein engineering perspective. Exp Cell Res 2011; 317: 1261-1269
• 2 Hamman JH, Enslin GM, Kotze AF. Oral delivery of peptide drugs: barriers and developments. BioDrugs 2005; 19: 165-177
• 3 Ratnaparkhi MP, Chaudhari SP, Pandya VA. Peptides and proteins in pharmaceuticals. Int J Curr Pharmaceut Res 2011; 3: 1-9
• 4 Leader B, Baca QJ, Golan DE. Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov 2008; 7: 21-39
• 5 Yun Y, Cho YW, Park K. Nanoparticles for oral delivery: targeted nanoparticles with peptidic ligands for oral protein delivery. Adv Drug Deliv Rev 2013; 65: 822-832
• 6 Park K, Kwon IC, Park K. Oral protein delivery: Current status and future prospect. React Funct Polym 2011; 71: 280-287
• 7 Renukuntla J, Vadlapudi AD, Patel A et al. Approaches for enhancing oral bioavailability of peptides and proteins. Int J Pharm 2013; 447: 75-93
• 8 Pivot X, Gligorov J, Müller V et al. PrefHer Study Group . Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol 2013; 14: 962-970
• 9 Hourcade-Potelleret F, Lemenuel-Diot A, McIntyre C et al. Use of a population pharmacokinetic approach for the clinical development of a fixed-dose subcutaneous formulation of trastuzumab. CPT Pharmacometrics Syst Pharmacol 2014; 3: e87
• 10 Burcombe R, Chan S, Simcock R et al. Subcutaneous trastuzumab (Herceptin^®): A UK Time and Motion study in comparison with intravenous formulation for the treatment of patients with HER2-positive early breast cancer. Adv Breast Can Res 2013; 2: 133-140
• 11 Bittner B, Richter WF, Hourcade-Potelleret F et al. Development of a subcutaneous formulation for trastuzumab – nonclinical and clinical bridging approach to the approved intravenous dosing regimen. Arzneimittelforschung 2012; 62: 401-409
• 12 Bittner B, Richter WF, Hourcade-Potelleret F et al. Non-clinical pharmacokinetic/pharmacodynamic and early clinical studies supporting development of a novel subcutaneous formulation for the monoclonal antibody rituximab. Drug Res (Stuttg) 2014; 64: 569-575
• 13 Gupta S, Jain A, Chakraborty M et al. Oral delivery of therapeutic proteins and peptides: a review on recent developments. Drug Deliv 2013; 20: 237-246
• 14 Fasano A. Innovative strategies for the oral delivery of drugs and peptides. Trends Biotechnol 1998; 16: 152-157
• 15 Barclay N, Tarallo M, Hendrikx T et al. Patient preference for oral versus injectable and intravenous methods of treatment for rheumatoid arthritis. Poster presented at the 16th Annual European Congress of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR-EU); November 2–6 2013 Dublin, Ireland
• 16 Borner MM, Schoffski P, de Wit R et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 2002; 38: 349-358
• 17 Dibonaventura MD, Wagner JS, Girman CJ et al. Multinational Internet-based survey of patient preference for newer oral or injectable Type 2 diabetes medication. Patient Prefer Adherence 2010; 4: 397-406
• 18 Melmed S, Popovic V, Bidlingmaier M et al. Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial. J Clin Endocrinol Metab 2015; 100: 1699-1708
• 19 Binkley N, Bolognese M, Sidorowicz-Bialynicka A et al. Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) Investigators . A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial. J Bone Miner Res 2012; 27: 1821-1829
• 20 Lee VHL, Dodda-Kashi S, Grass GM et al. Oral route of peptide and protein drug delivery. In: Lee VHL. (ed.) Peptide and protein drug delivery. New York: Marcel Dekker; 1991: 691-738
• 21 Werle M, Makhlof A, Takeuchi H. Oral protein delivery: a patent review of academic and industrial approaches. Recent Pat Drug Deliv Formul 2009; 3: 94-104
• 22 Woodley JF. Enzymatic barriers for GI peptide and protein delivery. Crit Rev Ther Drug Carrier Syst 1994; 11: 61-95
• 23 Wacher VJ, Silverman JA, Zhang Y et al. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci 1998; 87: 1322-1330
• 24 Toorisaka E, Ono H, Arimori K et al. Hypoglycemic effect of surfactant-coated insulin solubilized in a novel solid-in-oil-in-water (S/O/W) emulsion. Int J Pharm 2003; 252: 271-274
• 25 Niu M, Lu Y, Hovgaard L et al. Hypoglycemic activity and oral bioavailability of insulin-loaded liposomes containing bile salts in rats: the effect of cholate type, particle size and administered dose. Eur J Pharm Biopharm 2012; 81: 265-272
• 26 Lowman AM, Morishita M, Kajita M et al. Oral delivery of insulin using pH-responsive complexation gels. J Pharm Sci 1999; 88: 933-937
• 27 Liu X, Liu C, Zhang W et al. Oligoarginine-modified biodegradable nanoparticles improve the intestinal absorption of insulin. Int J Pharm 2013; 448: 159-167
• 28 Agarwal V, Nazzal S, Reddy IK et al. Transport studies of insulin across rat jejunum in the presence of chicken and duck ovomucoids. J Pharm Pharmacol 2001; 53: 1131-1138
• 29 Brinckerhoff LH, Kalashnikov VV, Thompson LW et al. Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27–35) peptide: implications for peptide vaccines. Int J Cancer 1999; 83: 326-334
• 30 Kidron M, Dinh S, Menachem Y et al. A novel per-oral insulin formulation: proof of concept study in non-diabetic subjects. Diabet Med 2004; 21: 354-357
• 31 Bechara C, Sagan S. Cell-penetrating peptides: 20 years later, where do we stand?. FEBS Lett 2013; 587: 1693-1702
• 32 Khafagy el-S, Morishita M. Oral biodrug delivery using cell-penetrating peptide. Adv Drug Deliv Rev 2012; 64: 531-539
• 33 Traverso G, Schoellhammer CM, Schroeder A et al. Microneedles for drug delivery via the gastrointestinal tract. J Pharm Sci 2015; 104: 362-367
• 34 www.emisphere.com [accessed October 2014]
• 35 Castelli MC, Wong DF, Friedman K et al. Pharmacokinetics of oral cyanocobalamin formulated with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC): an open-label, randomized, single-dose, parallel-group study in healthy male subjects. Clin Ther 2011; 33: 934-945
• 36 Lee CM, Chen CY, Chien RN et al. A double-blind randomized controlled study to evaluate the efficacy of low-dose oral interferon-alpha in preventing hepatitis C relapse. J Interferon Cytokine Res 2014; 34: 187-194
• 37 Bennett AL, Smith DW, Cummins MJ et al. Low-dose oral interferon alpha as prophylaxis against viral respiratory illness: a double-blind, parallel controlled trial during an influenza pandemic year. Influenza Other Respir Viruses 2013; 7: 854-862
• 38 http://www.bone-ltd.com [accessed October 2014]
• 39 Bone Ltd. Platform Technologies
• 40 http://www.merrionpharma.com [accessed October 2014]
• 41 http://www.oramed.com [accessed October 2014]
• 42 Eldor R, Kidron M, Arbi E. A Single-Blind, Two-Period Study to Assess the Safety and Pharmacodynamics of an Orally Delivered GLP-1 Analog (Exenatide) in Healthy Subjects. Poster presented at the 70th Scientific Sessions of the American Diabetes Association; June 25–29 2010 Orlando, FL
• 43 http://enterisbiopharma.com [accessed October 2014]
• 44 Henriksen K, Andersen JR, Riis BJ et al. Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1-31)NH(2)] in postmenopausal women with osteoporosis. Bone 2013; 53: 160-166
• 45 http://www.caratherapeutics.com [accessed October 2014]
• 46 http://www.chiasmapharma.com [accessed October 2014]
• 47 Tuvia S, Pelled D, Marom K et al. A novel suspension formulation enhances intestinal absorption of macromolecules via transient and reversible transport mechanisms. Pharm Res 2014; 31: 2010-2021
• 48 European Medicines Agency . Herceptin Summary of Product Characteristics. September 2014
• 49 European Medicines Agency . MabThera Summary of Product Characteristics. July 2014
• 50 European Medicines Agency . RoActemra Summary of Product Characteristics. September 2014
• 51 European Medicines Agency . Velcade Summary of Product Characteristics. April 2014
• 52 Ismael G, Hegg R, Muehlbauer S et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre randomised trial. Lancet Oncol 2012; 13: 869-878
• 53 Davies A, Merli F, Mihaljevic B et al. Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. Lancet Oncol 2014; 15: 343-352
• 54 Burmester GR, Rubbert-Roth A, Cantagrel A et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis 2014; 73: 69-74
• 55 Ogata A, Tanimura K, Sugimoto T et al. Musashi Study Investigators. Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2014; 66: 344-354
• 56 Moreau P, Pylypenko H, Grosicki S et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011; 12: 431-440
• 57 European Medicines Agency . Assessment report: Herceptin. June 2013
• 58 European Medicines Agency . Assessment report: MabThera. January 2014
• 59 European Medicines Agency . Assessment report: Velcade. June 2012
• 60 European Medicines Agency . Assessment report: RoActemra. February 2014
• 61 Bookbinder LH, Hofer A, Haller MF et al. A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Release 2006; 114: 230-241
• 62 Moreau P, Coiteux V, Hulin C et al. Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma. Haematologica 2008; 93: 1908-1911
• 63 Wynne C, Harvey V, Schwabe C et al. Comparison of subcutaneous and intravenous administration of trastuzumab: a phase I/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer. J Clin Pharmacol 2013; 53: 192-201
• 64 Salar A, Avivi I, Bittner B et al. Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study. J Clin Oncol 2014; 32: 1782-1791
• 65 Zhang X, Chen YC, Fettner S et al. Pharmacokinetics and pharmacodynamics of tocilizumab after subcutaneous administration in patients with rheumatoid arthritis. Int J Clin Pharmacol Ther 2013; 51: 620-630
• 66 Zhang X, Georgy A, Rowell L. Pharmacokinetics and pharmacodynamics of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, following single-dose administration by subcutaneous and intravenous routes to healthy subjects. Int J Clin Pharmacol Ther 2013; 51: 443-455
• 67 http://clinicaltrials.gov/ct2/show/NCT01200758 [accessed October 2014]
• 68 Ohta S, Tsuru T, Terao K et al. Mechanism-based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study). J Clin Pharmacol 2014; 54: 109-119
• 69 Morcos PN, Zhang X, McIntyre C et al. Pharmacokinetics and pharmacodynamics of single subcutaneous doses of tocilizumab administered with or without rHuPH20. Int J Clin Pharmacol Ther 2013; 51: 537-548
• 70 Kivitz A, Olech E, Borofsky M et al. Subcutaneous tocilizumab vs. placebo in combination with disease modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2014; 66: 1653-1661
• 71 Liang JF, Yang VC. Insulin-cell penetrating peptide hybrids with improved intestinal absorption efficiency. Biochem Biophys Res Commun 2005; 335: 734-738
• 72 Wang DD, Zhang S, Zhao H et al. Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials. J Clin Pharmacol 2009; 49: 1012-1024
• 73 Lui CY, Amidon GL, Berardi RR et al. Comparison of gastrointestinal pH in dogs and humans: implications on the use of the beagle dog as a model for oral absorption in humans. J Pharm Sci 1986; 75: 271-274
• 74 Musther H, Olivares-Morales A, Hatley OJ et al. Animal versus human oral drug bioavailability: do they correlate?. Eur J Pharm Sci 2014; 57: 280-291
• 75 Akabane T, Tabata K, Kadono K et al. A comparison of pharmacokinetics between humans and monkeys. Drug Metab Dispos 2010; 38: 308-316
• 76 Parrott N, Lukacova V, Fraczkiewicz G et al. Predicting pharmacokinetics of drugs using physiologically based modeling – application to food effects. AAPS J 2009; 11: 45-53
• 77 Stroh M, Duda DG, Takimoto CH et al. Translation of anticancer efficacy from nonclinical models to the clinic. CPT Pharmacometrics Syst Pharmacol 2014; 3: e128
• 78 Tuvia S, Atsmon J, Teichman SL et al. Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. J Clin Endocrinol Metab 2012; 97: 2362-2369
• 79 Mao CP, Brovarney MR, Dabbagh K et al. Subcutaneous versus intravenous administration of rituximab: pharmacokinetics, CD20 target coverage and B-cell depletion in cynomolgus monkeys. PLoS One 2013; 8: e80533